Table 5.
Antibiotic therapies
| Antibiotic, n (%) | Early responders n = 332 | Later responders n = 253 |
|---|---|---|
| Combinations | ||
| Penicillin or penicillin + β-lactamase inhibitor + macrolide |
50 (15.1) |
22 (8.7) |
| Cephalosporin (except cefuroxime) + macrolide |
33 (9.9) |
48 (19.0) |
| Cephalosporin (except cefuroxime) + fluoroquinolone |
25 (7.5) |
34 (13.4) |
| Penicillin or penicillin–β-lactamase + fluoroquinolone |
16 (4.8) |
17 (6.7) |
| Monotherapies | ||
| Amoxicillin–clavulanate |
75 (22.6) |
15 (5.9) |
| Amoxicillin |
25 (7.5) |
3 (1.2) |
| Ceftriaxone |
25 (7.5) |
16 (6.3) |
| Levofloxacin |
22 (6.6) |
16 (6.3) |
| Moxifloxacin |
15 (4.5) |
10 (4.0) |
| Ampicillin–sulbactam |
5 (1.5) |
3 (1.2) |
| Piperacillin–tazobactam |
4 (1.2) |
7 (2.8) |
| Azithromycin |
4 (1.2) |
3 (1.2) |
| Clarithromycin |
3 (0.9) |
3 (1.2) |
| Cefuroxime |
3 (0.9) |
2 (0.8) |
| Meropenem |
1 (0.3) |
2 (0.8) |
| Ciprofloxacin | 0 | 2 (0.8) |